SetPoint Medical

New vitamin-sized device giving hope to rheumatoid arthritis patients

According to the National Library of Medicine, rheumatoid arthritis (RA) affects about 1.3 million adults in the U.S. — some put the number closer to 1.5 million. RA is an autoimmune, chronic, progressive inflammatory disease where the immune system mistakenly attacks healthy joint tissue. It…

Arthritis & Osteoporosis Consultants of the Carolinas Treats First Patient in North Carolina with the SetPoint System®, a Device-based Treatment for Rheumatoid Arthritis

Milestone marks expansion of FDA-approved neuroimmune modulation therapy into Southeast VALENCIA, Calif. – June 29, 2026 – SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced that the first…

This San Antonio woman is the first in Texas to receive new rheumatoid arthritis implant

For nearly four decades, San Antonio resident Susan Perry struggled to manage the chronic pain from her rheumatoid arthritis, an autoimmune disease that occurs when the immune system mistakenly attacks the body’s tissues and joints. Perry, now 69, was diagnosed in her early 30s and cycled through…

A baby died in this neurosurgeon’s arms. What happened next changed everything we know about inflammation

The young neurosurgeon in training couldn’t shake the sense of devastation. A baby died in his arms as he tried to resuscitate her. Her grandmother had tripped in the kitchen with a pot of boiling water, causing severe burns as the 11-month-old baby crawled across the floor. Dr. Kevin J. Tracey was…

Cost-effectiveness of vagus nerve-mediated neuroimmune modulation for the treatment of moderate-to-severe rheumatoid arthritis

Abstract Aims Rheumatoid arthritis (RA) is associated with increased healthcare resource utilization and high-cost pharmacologic treatment. The objective of the current analysis was to evaluate the cost-effectiveness of vagus nerve-mediated neuroimmune modulation therapy (NIMT) using a novel…

SetPoint Medical Announces Publication of Cost-Effectiveness Study Confirming Neuroimmune Modulation Can Reduce Total Cost of Care and Improve Quality of Life for Patients with Rheumatoid Arthritis

VALENCIA, Calif. – May 14, 2026 – SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced the publication of a landmark, peer-reviewed cost-effectiveness study in the Journal of Medical…